As the pandemic wanes, a new report shows that most sponsors and CROs plan to continue using the clinical trial innovations postpandemic, and that fears of a “snap back” to the status quo are misplaced. But the survey also found that sponsors and CROs have very different views on how prepared they are to deploy certain innovations for the long haul.